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Abstract
Background The authors developed a new intragastric
balloon procedure with the objective of making it safer,
faster, and less expensive than the established ones. The
proposed procedure uses a new gastric balloon with
technical improvements in the placement and removal
procedures.
Methods From June 2006 to July 2007, 52 patients were
submitted to the new treatment with the Silimed Gastric
Balloon (SGB), as part of a multidisciplinary program
involving clinical, psychological, and behavioral
approaches.
Results The new placement and removal procedures of the
SGB were effective and safe in all the cases. Due to
simplicity and shortened duration of the procedures, all the
patients left the outpatient clinic in less than 1 h after the
placement or removal of the SGB. For the 14 patients who
had completed the 6-month treatment, the initial mean
weight, mean body mass index (BMI), and mean excess of
weight (EW) were, respectively, 100.7 kg, 35.7 kg/m2, and
30.0 kg. After the 6-month treatment, these values
decreased significantly: 89.4 kg, 31.8 kg/m2, and 19.6 kg.
Conclusions Preliminary data suggest that the procedure
with the new balloon comes forth as a safe and effective
alternative to the treatment of weight loss in patients with
appropriate indication of use.
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Introduction
In the last few years, obesity has become one of the main
worrisome public health problems of epidemic proportions,
both in developed and developing countries. This motivated
the specialists in bariatric medicine to continually improve
the established therapies for obesity treatment and develop
new procedures that can effectively address aspects, such as
safety and efficiency.
Among the recently improved minimally invasive
procedures, intragastric balloon has been one temporary
nonsurgical option that can promote weight loss in select
groups of obese patients by partially filling their stomach
and inducing a sense of early satiety [1–4].
In the present study, the authors propose a series of
technical improvements in the intragastric balloon proce-
dure with the objective of making it safer, faster, and less
expensive than the established ones. The proposed proce-
dure uses a new device—Silimed Gastric Balloon (SGB)—
with technical improvements in the placement and removal
procedures. Preliminary results of safety and efficiency of
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the placement and removal procedures are presented and
discussed along with preliminary data on weight loss and




This study included 52 patients (45 women), with mean age
of 37.1±10.5 years (15 to 65 years). They comprised two
groups of preobese and obese patients who failed to
respond to previous clinical treatment for weight loss:
those who did not meet the IFSO standards for bariatric
surgery, and those who were not willing to undergo
bariatric surgery. Their pretreatment mean weight was
96.5±22.5 kg (58.3 to 157 kg), mean BMI was 34.7±
5.2 kg/ m2 (25.6 to 50.1 kg/m2), and mean EW was 27.6±
16.6 kg (1.6 to 78.7 kg).
Device
The SGB design specifications are based on some require-
ments defined in the 1987 Tarpon Springs’s International
Workshop, for the safety and efficiency of intragastric
balloon designs [5].
The SGB is supplied empty, and is delicately rolled up
inside a thin silicon sheath. This makes its placement and
positioning in the gastric fundus possible by endoscopic
route. The device consists of a smooth and transparent
silicon shell that acquires a round format when filled with
saline solution. The filling is done by a tube with a poly-
tetrafluorethylene needle at its extremity, which is con-
nected to a self-sealing valve attached to the device shell.
Initial Protocol
The preprocedure was conducted by a multidisciplinary
team that comprised psychologist, nutritionist, bariatric
surgeon, and endoscopist. At this stage, information
regarding the patients’ eating habits and their previous
obesity treatments was compiled.
For the SGB procedure, the authors considered the
following as absolute contraindications: the presence of
hiatal hernia >5 cm, active peptic ulcer, severe esophagitis
(III and IV degree—Savarry Miller), hemorrhagic risk (e.g.,
esophagic or gastric varicose veins, hemorrhagic gastritis),
Crohn’s disease, cancer, diverticule and/or esophagic
stenosis, serious cardiopulmonary, renal or hepatic disease,
previous gastric surgery, psychological disturbances, sweet-
eaters, and lack of motivation or reluctance to follow the
treatment protocol. Free and informed consents from the
patients were obtained only after explaining to them the need
of the behavioral changes after the SGB placement, the
importance of the follow-up visits, and the risks inherent to
this procedure.
The SGB placement procedure was immediately preced-
ed by a diagnostic esophagogastroduodenoscopy to define
the gastric anatomy, verify the existence of structural
abnormality, if any, in the clinical conditions that are
contraindicative to SGB placement, and aspirate the gastric
content when necessary. After removing the endoscope, the
SGB was lubricated with surgical lidocaine gel to initiate
the insertion procedure.
Placement and Removal Procedures
Both procedures were performed under the usual sedation
of diagnostic endoscopy. In the placement procedure, the
extremity of SGB’s sheath was carefully anchored to the
endoscope extremity by using a polipectomy snare (Fig. 1).
Fig. 1 a The polipectomy snare
carefully tying the extremity
of the SGB’s sheath (only the
extremity of the sheath, and not
of the shell, is tied so that the
shell does not get damaged);
b Anchoring of the extremity
of the SGB’s sheath to the
extremity of the endoscope
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Then, the SGB was smoothly inserted into the stomach by
traction under direct visual examination (Fig. 2), released
by the polypectomy snare near the pylorus and finally
positioned in the gastric fundus by retrocession maneuver
followed by SGB traction by the introduction catheter. In
the gastric fundus, the SGB was filled under direct visual
examination with saline solution (mean of 650 ml), and
fixed volumes of Iopamiron® contrast (20 ml) and
methylene blue to 2% (10 ml), in the final approximate
proportion of 65:2:1. The filling procedure was continually
monitored so that a better adequacy of the SGB volume to
the gastric capacity was achieved. After the filling
procedure, the SGB was visually inspected for the detection
of possible deflation and confirmation of the correct
positioning in the gastric fundus (Fig. 3). Antiemetics and
antispasmodics were administered orally or intravenously
to control nausea and pain for 24 to 72 h when necessary. A
proton pump inhibitor (PPI) of a dosage of 40 to 80 mg/day
was prescribed for all the patients during the treatment.
The first part of the SGB removal procedure was the
positioning of a double silicon overtube in the patient’s
esophagus. Under direct visual observation, a hole was
made by endo-scissors in each SGB, and a catheter inserted
to empty the SGB. Alternatively, a specially developed
catheter containing a needle was used to empty the SGB.
Each completely emptied SGB was captured by a polipec-
tomy snare and pulled until part of the SGB was held in the
overtube, simultaneously allowing the removal of the whole
endoscopic apparatus.
Statistics
To confirm the normal distribution of the efficiency
variables of the 14 patients who completed the 6-month
treatment, the Shapiro-Wilks test for normality was used.
The t test for paired observations under significance of 0.01
was used to evaluate the preliminary effectiveness of the
proposed treatment. The descriptive statistics values are
presented in the sections of “Methods” and “Results” as
mean±standard deviation.
Results
In all cases, the SGBs were successfully placed and
removed under usual sedation of diagnostic endoscopy.
Fig. 2 To position the SGB in
the stomach, instead of pushing
the SGB without visual exami-
nation, as in an orogastric probe,
it is pulled by traction of the
endoscope under visual
examination
Fig. 3 a Final positioning of the
SGB in the gastric fundus.
b The SGB in the final stage
of the filling procedure
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The procedures are simple and fast; the mean placement
procedure time was 9 min (7–17 min), and mean removal
procedure time was 13 min (10–25 min). The patients left
the outpatient clinic in less than 1 h after the procedure.
There was no intercurrence during the procedures and no
instance of SGB loss in the esophagus or tracheal aspiration
during the removal of the device. The use of Iopamiron® in
the filling solution of SGB provided a better radiographic
vision of the device during the treatment, when necessary.
All the 14 patients who had completed the 6-month
treatment with SGB lost weight at the end of the treatment.
Table 1 and Fig. 4 summarize the results of effectiveness.
The t test for paired observations under a significance of
0.01 showed that these preliminary results were significant.
The only initial complications were episodes of nausea,
vomiting, and epigastric pain. Epigastric pain occurred in
11 patients (21%), leading to early termination of the
treatment.
There was no occurrence of late complications such as
serious esophagitis, peptic ulcer and gastric perforation or
erosion. The only late complications were two cases of
spontaneous deflation of the device, one occurring after the
6-month treatment and the other within almost 6 months of
treatment. In both cases, the deflated devices did not
migrate to the intestine and were successfully removed by
endoscopy, following the established protocol.
Discussion
The use of an intragastric device to induce the weight loss
in obese patients was first described in 1982 [6]. However,
the first gastric balloon designs did not yield the expected
results of weight loss. On the contrary, they were associated
with high incidence of complications, mainly as damage to
the gastric mucosa and spontaneous deflation of the device,
followed by intestinal obstruction in some cases [6–9]. This
poor performance was due to technical aspects, such as the
filling of the devices with air and the presence of a low
resistant balloon shell with rough surface.
In 1999 was used a gastric balloon of silicon filled with
saline solution and with a design that the manufacturer
recommended its usage for 6 months [10]. Ever since,
significant results have been obtained with this new balloon
[1–4]. More recently, a prospective, double-blind, random-
ized, sham-controlled, and crossover study demonstrated
that the procedure with the new device was more effective
Table 1 Efficiency results of treatment with SGB in the 14 patients who had completed the 6-month treatment
Patient no. Filling solution (ml) Initial Weight (kg) Initial BMI (kg/m2) Final BMI (kg/m2) Weight Loss (kg) EWL (%)
1 650 80 30.5 27.0 9.0 62.5
2 660 99 34.3 32.0 6.3 23.5
3 580 100 38.1 35.2 7.5 21.8
4 620 91 34.2 29.8 11.8 48.0
5 630 85 32.0 27.8 11.0 59.2
6 600 88 35.2 30.8 11.0 43.0
7 700 155.1 44.8 38.4 22.1 32.2
8 620 85 34.9 32.9 5.0 20.7
9 650 86 32.6 30.5 5.6 27.7
10 700 114.6 36.6 31.9 14.6 40.2
11 650 85 30.8 25.7 14.0 87.0
12 590 100 36.7 36.4 1.0 3.1
13 690 157 50.1 43.7 20.0 25.4
14 620 84 29.4 22.5 19.7 156.4
Mean 640±38.6 107.7±25.1 35.7±5.7 31.8±5.5 11.3±6.2 46.5±36.7
Range 580 to 700 80.0 to 157.0 29.4 to 50.1 22.5 to 43.7 1.0 to 22.1 3.1 to 156.4
Fig. 4 Boxplot showing the means and dispersions of the initial and
final BMI data of the 14 patients who had completed the 6-month
treatment with SGB
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in treating obese patients than the sham procedure with
restricted diet [3].
In the present study, based on the established concept of
the intragastric balloon, the objective was to present an
even safer and more effective treatment alternative for the
weight loss in patients with appropriate indication. For this,
the authors used a new intragastric balloon (SGB), and
introduced technical improvements in the placement and
removal procedures of the device.
In this series, all the SGBs were successfully placed and
removed by endoscopy, with no intercurrences during the
procedures. Both the procedures are simple and fast and,
therefore, perfectly feasible under the usual sedation of
diagnostic endoscopy, and under the ambulatory level in
endoscopic suite, which avoids the risks and costs
associated with general anesthesia and the surgical block.
Anchoring the extremity of the SGB’s sheath to the
extremity of the endoscope made the placement of the
device by traction possible: placement by traction appeared
to be simpler and more effective than placement by a tube
that pushes the device without visual monitoring, as in the
orogastric probe. In this stage, the direct visual monitoring
enabled the fast positioning of the SGB in the gastric
fundus, thereby reducing the excessive manipulation of the
endoscope and the consequent risk of damage to the
pharynx. The mean duration of the procedure—9 min (7
to 17 min)—was shorter than the good results presented in
some clinical series: Hervé et al. [11] and Genco et al. [3]
obtained, respectively, a mean time of 14.5 min (10 to
30 min) and 15 min (10 to 20 min).
Although SGB has a radiopaque mark around the valve,
the use of Iopamiron® in the filling solution of the SGB
contributes to obtaining more clearly defined images on the
correct placement of the balloon, whenever necessary. This
contrast in the filling solution facilitates fine volumetric
analysis of SGB, by overlapping of X-rays, in cases of
suspected progressive deflation of the device. Moreover,
according to the information supplied by the manufacturer
of the device, the filling solution neither reacted with the
SGB shell nor reduced the useful life of the device.
The stable catch of the SGB by the polipectomy snare,
followed by the joining of SGB directly to the overtube,
and the simultaneous removal of the whole endoscopic
apparatus, constituted a very safe and effective removal
procedure in all cases of 6-month treatment completion,
and interrupted treatment due to intolerance to the device
or balloon deflation. Even in the high pressure area of
the esophagus, at the level of the cricopharyngeal muscle,
the overtube containing the SGB passed through easily,
thus minimizing the risk of damage to the esophagus or
device loss in the digestive tract. The use of the overtube
practically annulled the risk of tracheal aspiration of
saline solution or food residues, thus making the procedure
of tracheal intubation unnecessary for controlling these
risks. Furthermore, the shortened removal time of SGB
resulted in using fewer antispasmodics and decreasing
thereby the patient’s discomfort, mainly due to lower
transparietal stimulation by the endoscopic apparatus and
consequent reduction of the spasms of the cardia and the
esophagus.
All the 14 patients who completed the 6-month treatment
with SGB lost weight, the mean loss being 11.3±6.2 kg,
which is less than the losses of other larger clinical series:
Hervé et al. [11] and Evans and Scott [1] obtained,
respectively, a mean weight loss of 12 kg in 100 patients
and 15 kg in 58 patients. The use of the t test for paired
observations showed that the preliminary results of weight
loss were significant in this group of 14 patients, although
the possibility of placebo effect or weight loss due only to
behavioral changes can not be excluded. Nonetheless, two
aspects that reinforce the effectiveness of SGB merit
emphasis: (1) The recent publication of Genco et al. [3]
showing that the intragastric balloon concept in the
treatment of the weight loss in obese patients is more
effective than the sham procedure associated with restricted
diet. (2) The failure history of the patients of the present
series to previous clinical treatments for weight loss.
In this series, there was no occurrence of any serious late
complication such as erosion or peptic ulcer, except for two
cases of late spontaneous deflation of the balloon. Even in
these cases, the patients lost weight satisfactorily, and the
devices were successfully removed by gastric endoscopy,
thus reinforcing the concept of safety and effectiveness of
the SGB treatment. The continuous use of the PPI during
treatment is mandatory to ensure this safety by protecting
the gastric mucosa and the balloon shell from the
deleterious effect of the hydrochloric acid. As a result of
this continuous use and consequent reduction in gastric
acidity, the patient’s digestive tract becomes a more
favorable environment to the Candida sp, and this explains
the colonization of the SGB shell by these fungi in some
of the cases. In the symptomatic cases of candidiasis,
during the SGB treatment, nistatin can be prescribed for
the patient.
The treatment of weight loss using a new intragastric
balloon presented encouraging preliminary results in terms
of safety and effectiveness in eligible patients. Thus, the
SGB can be considered a new reversible procedure for
weight loss, which is minimally invasive and has low
morbidity rate as compared to other bariatric procedures.
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